Our Investments for Changing Healthcare
Quadria Capital is an independent healthcare-focused private equity firm with US$3.5 billion AUM, investing in the healthcare sector of some of the world’s fastest-growing economies in South Asia and Southeast Asia.
We are dedicated to the core belief that access to healthcare is a fundamental human right. We invest in leading healthcare businesses across Asia, partnering with visionary entrepreneurs to achieve exceptional growth, financial returns, and drive meaningful social impact.

OVERVIEW
We are Quadria Capital.

Building regional leaders
We focus on partnering with large regional healthcare companies and, with our active investment strategy, help them grow into regional leaders.

Delivering superior returns
We are a trusted partner to many of the world’s leading institutional investors. As careful stewards of capital, we place primary importance on our responsibilities towards our investors.

Creating lasting impact
Creating positive social impact is integral to our firm. We strive to touch as many lives as possible to improve healthcare outcomes, to make high quality healthcare affordable and more accessible.
OUR FOCUS
Focus Sectors
With changing lifestyles and urbanisation, rise in chronic diseases and a huge demand-supply gap, the challenge of bringing high quality healthcare at affordable prices in Asia could not be more acute. Quadria invests in high-growth healthcare markets within South and Southeast Asia that have strong underlying fundamentals and favorable market dynamics, where we can bring about meaningful change with our capital and expertise.
Healthcare Delivery
Asia’s healthcare services market is expected to grow 7% to US$ 1.4 trillion by 2026
The Asian healthcare services market is expected to grow at 7% CAGR to reach US$ 1.4 trillion by 2026.
Increasing disposable incomes, sedentary lifestyles, increase in chronic diseases and aging population is leading the demand for quality healthcare services in Asia. However, there exists a huge demand supply gap in terms of both clinical talent as well as supply infrastructure. Due to low public spending on healthcare, more than 70% of new hospital beds are expected to provided by the private sector, creating a huge investment opportunity.
Life Sciences
Asia’s pharmaceuticals market is expected to grow at 5% to reach US$ 305 billion in 2029
The Asian pharmaceuticals market is expected to grow at 5% CAGR to reach US$ 305 billion by 2030. The share of emerging markets in the global pharmaceutical market is expected to increase significantly over the next decade.
Several factors such as increasing patent expiries in the regulated markets, shift towards differentiated & specialty products and increasing trend of consolidation is expected to create attractive growth opportunities for Asian players, many of whom are amongst the largest generics drug companies globally.
Medical Technology
Asia’s medical technology market is poised to grow at over 10% through 2030
The Asian medical devices market is projected to grow at over 10% CAGR to reach US$ 225 billion by 2030. Local firms are aiming for broader range of patient interactions through redrafting their business models by offering appropriate products and services that are tailored to meet the local needs of each market.
Frugal innovation, low-cost environment and desire to move up the value chain by shifting from manufacturing of medical supplies and consumables to more complex devices would lead the growth of the sub-segment in the region.
Associated Healthcare Services
It is moving away from being a mostly provider driven industry to a consumer driven industry
The healthcare ecosystem is witnessing a paradigm shift in the way the services are being delivered and consumed. It is moving away from being a mostly provider driven industry to a consumer driven industry.
All these changes are driven by an underlying need to provide empowerment, convenience and an enhanced experience to the patients and the proliferation is fuelled by technology and entrepreneurship. All these factors are coming together to create specific pockets of opportunities such as home healthcare, health insurance and healthcare retail chains.
THE QUADRIA TEAM
Quadria has one of the largest dedicated healthcare teams in Asia.

Abrar Mir
Managing Partner

Dr. Amit Varma
Managing Partner

Sunil Thakur
Partner and Head of South Asia

Ewan Davis
Partner and Head of Southeast Asia

Abhishek Yadav
Managing Director

Joseph Khoo
Managing Director

Rahul Agarwal
Managing Director

Janice Trinh
Director

Arif Sidharta
Vice President

Arshita Kapoor
Vice President

Ong Si Keat
Vice President

Raghav Bhatnagar
Vice President

Tushar Garg
Senior Associate

Daniel Chin
Senior Associate

Mark Xu
Senior Associate

Shikha Gupta
Senior Associate

Gabriel Teo
Associate

Toan Nguyen
Associate

Vikrant Parashar
Strategic Associate

Sachi Vats
Analyst

Anh Pham
Director

Anjli Kaushal
Director

Shivani Sahai
Head of ESG and Impact

Carina Tai
Assistant Manager

Peter Goodson
Chairman

Dr. Jonathan Goldman
Director

Bhasker Iyer
Director

Hank Klakurka
Director

Steven Hodge
Director

Ian Mcleod
Director

K Srivatsan
Director

Thomas C. Franco
Director

Wilder Fulford
Director

Tri Pham
Regional Advisory Group

Gerald Ng
Managing Director

Dawn Ho
Investor Relations Associate

Christy Oi
Chief Operating Officer

Devendra Sharma
Chief Financial Officer

Raveen
Compliance Manager

Kartikey Singhal
Finance Manager

Nivedita Pant
Office Manager

Yee Lu Ng
Finance Controller

Belinda Lee
Finance Manager, SEA

Samantha Tham
Office Manager

Lux Tan
Office Administrator